Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all

Clinical Infectious Diseases

Volumn 57, Issue SUPPL.2, 2013, Pages

  Bruggmann, Philip ^a   Litwin, Alain H ^b  

^a Arud Centres for Addiction Medicine   (Switzerland)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Hepatitis C; IDU; Integrated care; Management; People who inject drugs

Indexed keywords

BUPRENORPHINE; METHADONE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADDICTION; ADULT; ARTICLE; CLINICAL TRIAL; DIRECTLY OBSERVED THERAPY; DRUG TOLERABILITY; FEMALE; GENERAL PRACTITIONER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; TERTIARY HEALTH CARE;

HEPATITIS C; IDU; INTEGRATED CARE; MANAGEMENT; PEOPLE WHO INJECT DRUGS;

DELIVERY OF HEALTH CARE; HEALTH SERVICES ADMINISTRATION; HEPATITIS C; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84881004592     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit271     Document Type: Article

References (50)

1. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-83.
2. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-33.
3. Grebely J, Petoumenos K, Matthews GV, et al. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: the ATAHC Study. Drug Alcohol Depend 2010; 107: 244-9.
4. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-8.
5. Strathdee SA, Latka M, Campbell J, et al. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005; 40(suppl 5):S304-12.
6. Lindenburg CE, Lambers FA, Urbanus AT, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011; 23: 23-31.
7. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54: 1137-44.
8. Matser A, Urbanus A, Geskus R, et al. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Addiction 2012; 107: 614-23.
9. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology 2005; 42: 711-23.
10. Thomas DL, Leoutsakas D, Zabransky T, Kumar MS. Hepatitis C in HIV-infected individuals: cure and control, right now. J Int AIDS Soc 2011; 14:22.
11. Grebely J, Bryant J, Hull P, et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat 2011; 18:e104-16.
12. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50: 1750-5.
13. Swan D, Long J, Carr O, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS 2010; 24: 753-62.
14. Bruggmann P. Accessing hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat 2012; 19: 829-35.
15. Reimer J, Haasen C. Need-adapted HCV-treatment setting for injection drug users. Lancet 2009; 373: 2090-1.
16. Paterson BL, Backmund M, Hirsch G, Yim C. The depiction of stigmatization in research about hepatitis C. Int J Drug Policy 2007; 18: 364-73.
17. Moore GA, Hawley DA, Bradley P. Hepatitis C: studying stigma. Gastroenterol Nurs 2008; 31: 346-52.
18. Litwin AH, Kunins HV, Berg KM, et al. Hepatitis C management by addiction medicine physicians: results from a national survey. J Subst Abuse Treat 2007; 33: 99-105.
19. Grebely J, Tyndall MW. Management of HCV and HIV infections among people who inject drugs. Curr Opin HIVAIDS 2011; 6: 501-7.
20. Bini EJ, Kritz S, Brown LS Jr., Robinson J, Alderson D, Rotrosen J. Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States. J Addict Dis 2011; 30: 98-109.
21. Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010; 22: 270-7.
22. Curcio F, Di MF, Capraro C, et al. Together to take care: multidisciplinary management of hepatitis C virus treatment in randomly selected drug users with chronic hepatitis. J Addict Med 2010; 4: 223-32.
23. Litwin AH, Harris KA Jr., Nahvi S, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009; 37: 32-40.
24. Belfiori B, Ciliegi P, Chiodera A, et al. Peginterferon plus ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. Dig Liver Dis 2009; 41: 303-7.
25. Jack K, Willott S, Manners J, Varnam MA, Thomson BJ. Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Aliment Pharmacol Ther 2009; 29: 38-45.
26. Hill WD, Butt G, Alvarez M, Krajden M. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol 2008; 22: 27-32.
27. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2012; 56: 806-16.
28. Druss BG, Rohrbaugh RM, Levinson CM, Rosenheck RA. Integrated medical care for patients with serious psychiatric illness: a randomized trial. Arch Gen Psychiatry 2001; 58: 861-8.
29. Saxon AJ, Malte CA, Sloan KL, et al. Randomized trial of onsite versus referral primary medical care for veterans in addictions treatment. Med Care 2006; 44: 334-42.
30. Laine C, Hauck WW, Gourevitch MN, Rothman J, Cohen A, Turner BJ. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. JAMA 2001; 285: 2355-62.
31. Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA 2001; 286: 1715-23.
32. Seidenberg A, Rosemann T, Senn O. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting. BMC Infect Dis 2013; 13:9.
33. Harris KA Jr., Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010; 4: 20-6.
34. Charlebois A, Lee L, Cooper E, Mason K, Powis J. Factors associated with HCV antiviral treatment uptake among participants of a communitybased HCV programme for marginalized patients. J Viral Hepat 2012; 19: 836-42.
35. Kresina TF, Bruce RD, Lubran R, Clark HW. Integration of viral hepatitis services into opioid treatment programs. J Opioid Manag 2008; 4: 369-81.
36. Wilkinson M, Crawford V, Tippet A, et al. Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use. Aliment Pharmacol Ther 2009; 29: 29-37.
37. Moussalli J, Delaquaize H, Boubilley D, et al. Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract 2010; doi:10.1155/2010/261472.
38. Brunner N, Senn O, Rosemann T, Falcato L, Bruggmann P. Hepatitis C treatment for multimorbid patients with substance use disorder in a primary care-based integrated treatment centre: a retrospective analysis [Epub ahead of print 8 April 2013]. Eur J Gastroenterol Hepatol 2013; doi:10.1097/MEG. 0b013e32836140bb.
39. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364: 2199-207.
40. Evon DM, Simpson K, Kixmiller S, et al. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol 2011; 106: 1777-86.
41. Larrey D, Salse A, Ribard D, et al. Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon- alpha2a and ribavirin. Clin Gastroenterol Hepatol 2011; 9: 781-5.
42. Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/ medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006; 101: 2254-62.
43. Martinez AD, Dimova R, Marks KM, et al. Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat 2012; 19: 47-54.
44. Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend 2011; 113: 192-9.
45. Gourevitch MN, Wasserman W, Panero MS, Selwyn PA. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis 1996; 15: 93-104.
46. Bonkovsky HL, Tice AD, Yapp RG, et al. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol 2008; 103: 2757-65.
47. Krook AL, Stokka D, Heger B, Nygaard E. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur Addict Res 2007; 13: 216-21.
48. Waizmann M, Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Subst Abuse Treat 2010; 38: 338-45.
49. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007; 19: 741-7.
50. Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. J Subst Abuse Treat 2012; 43: 424-32.